Praesto™ 70 CH1 Chromatography Resin

As antibody variants, including bispecifics, become more integral to therapeutic development, efficient purification solutions are critical. Praesto™ 70 CH1 is engineered to address these challenges by targeting CH1 antibody domains. With up to twice the dynamic binding capacity of traditional resins and enhanced alkaline stability, Praesto™ 70 CH1 supports the adoption of standard CIP protocols, simplifying complex purification procedures.

Purolite's patented Jetting technology ensures a uniform particle size, offering high-quality, consistent performance while promoting sustainability. This advanced manufacturing process reduces harmful solvents and water usage, accelerating time to market with fewer production steps. For pharmaceutical manufacturers developing innovative therapeutic molecules, Praesto™ 70 CH1 provides a highly efficient, reliable, and sustainable solution for bispecific and antibody fragment purification.